1. B. Zuckerman, The Dual Antiplatelet Therapy (DAPT) Trial: An FDA Perspective, https://www.cardiac-safety.org/think-tanks/presentations-1/presentations-2009/4%20-%20Bram%20Zuckerman.pdf
2. R. Waksman, Drug-Eluting Stents: Will the Transformation to Bioabsorption Make Durable Polymers Obsolete, Cardiovasc. Revasc. Med., 2013, 14, p 69–70
3. S. Wood, Cordis Quits Coronary Stent Business, Dropping Cypher, Nevo DES. June 15, 2011 HeartWire, http://www.theheart.org/article/1238785.do
4. E.H. Christiansen, L.O. Jensen, P. Thayssen, H.H. Tilsted, L.R. Krusell, K.N. Hansen et al., Biolimus-Eluting Biodegradable Polymer-Coated Stent Versus Durable Polymer Coated Sirolimus-Eluting Stent in Unselected Patients Receiving Percutaneous Coronary Intervention (SORT OUT V): A Randomised Non-inferiority Trial, Lancet, 2013, 381, p 661. doi: 10.1016/S0140-6736(12)61962-X
5. P.C. Smits, S. Hofma, M. Togni, N. Vazquez, M. Valdes, V. Voudris et al., Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent (COMPARE II): A Randomised, Controlled, Non-inferiority Trial. Lancet, 2013, 381, p 651. doi: 10.1016/S0140-6736(12)61852-2